JP2017532302A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017532302A5 JP2017532302A5 JP2017512684A JP2017512684A JP2017532302A5 JP 2017532302 A5 JP2017532302 A5 JP 2017532302A5 JP 2017512684 A JP2017512684 A JP 2017512684A JP 2017512684 A JP2017512684 A JP 2017512684A JP 2017532302 A5 JP2017532302 A5 JP 2017532302A5
- Authority
- JP
- Japan
- Prior art keywords
- tev
- utr
- sequence
- human
- gaopt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 108020004705 Codon Proteins 0.000 description 2
- 241000723792 Tobacco etch virus Species 0.000 description 2
- 108020005345 3' Untranslated Regions Proteins 0.000 description 1
- 108020003589 5' Untranslated Regions Proteins 0.000 description 1
- 101000899111 Homo sapiens Hemoglobin subunit beta Proteins 0.000 description 1
- 101001063991 Homo sapiens Leptin Proteins 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 102000049953 human LEP Human genes 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462046487P | 2014-09-05 | 2014-09-05 | |
| US62/046,487 | 2014-09-05 | ||
| PCT/US2015/048535 WO2016037053A1 (en) | 2014-09-05 | 2015-09-04 | Lipids and lipid compositions for the delivery of active agents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017532302A JP2017532302A (ja) | 2017-11-02 |
| JP2017532302A5 true JP2017532302A5 (enExample) | 2018-10-18 |
| JP6731912B2 JP6731912B2 (ja) | 2020-07-29 |
Family
ID=54256820
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017512684A Active JP6731912B2 (ja) | 2014-09-05 | 2015-09-04 | 活性物質の送達用の脂質および脂質組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US10125092B2 (enExample) |
| EP (1) | EP3188760B1 (enExample) |
| JP (1) | JP6731912B2 (enExample) |
| CN (1) | CN107072946B (enExample) |
| ES (1) | ES2969956T3 (enExample) |
| WO (1) | WO2016037053A1 (enExample) |
Families Citing this family (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9988627B2 (en) | 2013-10-04 | 2018-06-05 | Novartis Ag | Formats for organic compounds for use in RNA interference |
| WO2015051045A2 (en) | 2013-10-04 | 2015-04-09 | Novartis Ag | 3'END CAPS FOR RNAi AGENTS FOR USE IN RNA INTERFERENCE |
| WO2015050871A2 (en) | 2013-10-04 | 2015-04-09 | Novartis Ag | Organic compounds to treat hepatitis b virus |
| CA3177878A1 (en) | 2014-04-23 | 2015-10-29 | Modernatx, Inc. | Nucleic acid vaccines |
| WO2016037053A1 (en) * | 2014-09-05 | 2016-03-10 | Novartis Ag | Lipids and lipid compositions for the delivery of active agents |
| US10822357B2 (en) * | 2015-08-28 | 2020-11-03 | Sekisui Medical Co., Ltd. | Benzyl compound |
| CA3002922A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| DK3386484T3 (da) | 2015-12-10 | 2022-07-04 | Modernatx Inc | Sammensætninger og fremgangsmåder til afgivelse af terapeutiske midler |
| AU2017244143B2 (en) * | 2016-03-30 | 2024-06-20 | Intellia Therapeutics, Inc. | Lipid nanoparticle formulations for CRISPR/Cas components |
| US10967057B2 (en) | 2016-06-02 | 2021-04-06 | Glaxosmithkline Biologicals S.A. | Zika viral antigen constructs |
| US11878060B2 (en) | 2016-08-07 | 2024-01-23 | Novartis Ag | mRNA-mediated immunization methods |
| BE1024774B1 (fr) | 2016-09-29 | 2018-07-02 | Glaxosmithkline Biologicals Sa | Compositions et procedes de traitement |
| GB201616904D0 (en) | 2016-10-05 | 2016-11-16 | Glaxosmithkline Biologicals Sa | Vaccine |
| EP3528821A4 (en) | 2016-10-21 | 2020-07-01 | ModernaTX, Inc. | HUMAN CYTOMEGALOVIRUS VACCINE |
| EP4043031A3 (en) | 2016-11-17 | 2022-11-23 | GlaxoSmithKline Biologicals SA | Zika viral antigen constructs |
| EP3595713A4 (en) | 2017-03-15 | 2021-01-13 | ModernaTX, Inc. | Respiratory syncytial virus vaccine |
| MX2019014435A (es) | 2017-05-30 | 2020-01-27 | Glaxosmithkline Biologicals Sa | Procedimientos para la fabricacion de un arn encapsulado en liposoma. |
| WO2018232357A1 (en) | 2017-06-15 | 2018-12-20 | Modernatx, Inc. | Rna formulations |
| JP2020530765A (ja) * | 2017-07-17 | 2020-10-29 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | リサウイルス抗原構築物 |
| MX2020002348A (es) | 2017-08-31 | 2020-10-08 | Modernatx Inc | Métodos de elaboración de nanopartículas lipídicas. |
| EP3461497A1 (en) | 2017-09-27 | 2019-04-03 | GlaxoSmithKline Biologicals S.A. | Viral antigens |
| US11911453B2 (en) | 2018-01-29 | 2024-02-27 | Modernatx, Inc. | RSV RNA vaccines |
| CA3109165A1 (en) | 2018-08-17 | 2020-02-20 | Glaxosmithkline Biologicals Sa | Immunogenic compositions and uses thereof |
| CN109260174B (zh) * | 2018-09-04 | 2021-10-15 | 中山大学 | 一种治疗性蛋白纳米颗粒的高通量制备方法 |
| WO2020061284A1 (en) | 2018-09-19 | 2020-03-26 | Modernatx, Inc. | Peg lipids and uses thereof |
| EP4509118A3 (en) | 2018-09-19 | 2025-05-14 | ModernaTX, Inc. | High-purity peg lipids and uses thereof |
| JP2022501367A (ja) | 2018-09-20 | 2022-01-06 | モデルナティエックス インコーポレイテッドModernaTX, Inc. | 脂質ナノ粒子の調製及びその投与方法 |
| EP3646854B1 (en) * | 2018-10-30 | 2022-08-03 | PolyPlus Transfection | Compositions for transfecting mrna into a cell and their applications |
| IL314386A (en) | 2018-12-05 | 2024-09-01 | Intellia Therapeutics Inc | amine modified lipids |
| EP3893927A1 (en) * | 2018-12-14 | 2021-10-20 | GlaxoSmithKline Biologicals S.A. | Heterologous prime boost vaccine compositions and methods |
| MY207334A (en) * | 2019-03-08 | 2025-02-19 | Massachusetts Inst Technology | Synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy |
| KR20220035457A (ko) | 2019-07-21 | 2022-03-22 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 치료 바이러스 백신 |
| WO2021038508A1 (en) | 2019-08-30 | 2021-03-04 | Glaxosmithkline Biologicals Sa | Jet mixing lipid nanoparticle manufacturing process |
| AU2020382378A1 (en) * | 2019-11-15 | 2022-06-30 | Daiichi Sankyo Company, Limited | Nucleic acid lipid particle vaccine encapsulating HPV mRNA |
| KR20220123536A (ko) | 2020-01-09 | 2022-09-07 | 가이드 테라퓨틱스 엘엘씨 | 나노물질 |
| US20240269266A1 (en) * | 2020-04-14 | 2024-08-15 | The Regents Of The University Of California | Broad-spectrum multi-antigen pan-coronavirus vaccine |
| EP4135761A1 (en) | 2020-04-16 | 2023-02-22 | GlaxoSmithKline Biologicals S.A. | Sars cov-2 spike protein construct |
| EP4161570A1 (en) | 2020-06-05 | 2023-04-12 | GlaxoSmithKline Biologicals S.A. | Modified betacoronavirus spike proteins |
| EP4171629A1 (en) | 2020-06-29 | 2023-05-03 | GlaxoSmithKline Biologicals S.A. | Adjuvants |
| US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| EP4267593A2 (en) | 2020-12-23 | 2023-11-01 | GlaxoSmithKline Biologicals SA | Self-amplifying messenger rna |
| EP4032546A1 (en) | 2021-01-20 | 2022-07-27 | GlaxoSmithKline Biologicals S.A. | Therapeutic viral vaccine |
| KR20230135060A (ko) | 2021-01-20 | 2023-09-22 | 빔 테라퓨틱스, 인크. | 생분해성 특징을 포함하는 나노물질 |
| KR20230131863A (ko) * | 2021-01-20 | 2023-09-14 | 빔 테라퓨틱스, 인크. | 나노물질 |
| JP7683017B2 (ja) * | 2021-02-05 | 2025-05-26 | イモーナ（ハンチョウ）バイオテクノロジー カンパニー リミテッド | イオン化可能な脂質分子、その製造方法及び脂質ナノ粒子の製造における応用 |
| CN112961065B (zh) * | 2021-02-05 | 2023-03-14 | 嘉晨西海(杭州)生物技术有限公司 | 一种可电离脂质分子及其制备方法及其在制备脂质纳米颗粒的应用 |
| US11524023B2 (en) | 2021-02-19 | 2022-12-13 | Modernatx, Inc. | Lipid nanoparticle compositions and methods of formulating the same |
| CN117377491A (zh) | 2021-03-26 | 2024-01-09 | 葛兰素史克生物有限公司 | 免疫原性组合物 |
| TW202307211A (zh) * | 2021-05-19 | 2023-02-16 | 日商第一三共股份有限公司 | Hpv感染症疫苗 |
| WO2022248353A1 (en) | 2021-05-24 | 2022-12-01 | Glaxosmithkline Biologicals Sa | Adjuvants |
| EP4352247A1 (en) | 2021-06-09 | 2024-04-17 | GlaxoSmithKline Biologicals s.a. | Release assay for determining potency of self-amplifying rna drug product and methods for using |
| EP4387596A1 (en) | 2021-08-16 | 2024-06-26 | GlaxoSmithKline Biologicals SA | Low-dose lyophilized rna vaccines and methods for preparing and using the same |
| US20240350410A1 (en) | 2021-08-16 | 2024-10-24 | Glaxosmithkline Biologicals Sa | Freeze-drying of lipid nanoparticles (lnps) encapsulating rna and formulations thereof |
| WO2023020994A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Novel methods |
| WO2023020993A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Novel methods |
| WO2023020992A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Novel methods |
| CA3229889A1 (en) | 2021-09-03 | 2023-03-09 | Glaxosmithkline Biologicals Sa | Substitution of nucleotide bases in self-amplifying messenger ribonucleic acids |
| WO2023104114A2 (en) * | 2021-12-07 | 2023-06-15 | Immorna (hangzhou) Biotechnology Co., Ltd. | Rna formulations and lipids |
| CN118401547A (zh) * | 2021-12-17 | 2024-07-26 | 嘉晨西海(杭州)生物技术有限公司 | 白细胞介素-12自我复制rna和方法 |
| JP2023130120A (ja) * | 2022-03-07 | 2023-09-20 | スペラファーマ株式会社 | ペプチド合成方法 |
| KR20240166554A (ko) * | 2022-03-25 | 2024-11-26 | 세일 바이오메디슨스, 인크. | 신규한 이온화 가능 지질 및 지질 나노입자, 및 이를 사용하는 방법 |
| JP2023181989A (ja) * | 2022-06-13 | 2023-12-25 | 上海臻上医薬科技有限公司 | マイクロニードル注射製剤およびその使用 |
| WO2023242817A2 (en) | 2022-06-18 | 2023-12-21 | Glaxosmithkline Biologicals Sa | Recombinant rna molecules comprising untranslated regions or segments encoding spike protein from the omicron strain of severe acute respiratory coronavirus-2 |
| WO2024019936A1 (en) | 2022-07-20 | 2024-01-25 | Beam Therapeutics Inc. | Nanomaterials comprising triols |
| WO2024068545A1 (en) | 2022-09-26 | 2024-04-04 | Glaxosmithkline Biologicals Sa | Influenza virus vaccines |
| CN120322429A (zh) * | 2022-10-28 | 2025-07-15 | 先进核糖核酸疫苗(Arv)技术股份有限公司 | 基于维生素的脂质以及包含其的脂质纳米颗粒 |
| WO2024120490A1 (en) * | 2022-12-07 | 2024-06-13 | Immorna (hangzhou) Biotechnology Co., Ltd. | Self-replicating rna vaccines and methods of use |
| CN120456919A (zh) | 2022-12-19 | 2025-08-08 | 葛兰素史克生物有限公司 | 乙型肝炎组合物 |
| WO2024160936A1 (en) | 2023-02-03 | 2024-08-08 | Glaxosmithkline Biologicals Sa | Rna formulation |
| GB202302092D0 (en) | 2023-02-14 | 2023-03-29 | Glaxosmithkline Biologicals Sa | Analytical method |
| WO2024187158A1 (en) * | 2023-03-08 | 2024-09-12 | The Regents Of The University Of California | Benzaldehyde acetal acid-degradable amphiphilic lipid and self-assembling peptides |
| WO2024223724A1 (en) | 2023-04-27 | 2024-10-31 | Glaxosmithkline Biologicals Sa | Influenza virus vaccines |
| WO2024223728A1 (en) | 2023-04-27 | 2024-10-31 | Glaxosmithkline Biologicals Sa | Influenza virus vaccines |
| US12311033B2 (en) | 2023-05-31 | 2025-05-27 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025011529A2 (en) | 2023-07-07 | 2025-01-16 | Shanghai Circode Biomed Co., Ltd. | Circular rna vaccines for seasonal flu and methods of uses |
| WO2025045142A1 (en) | 2023-08-29 | 2025-03-06 | Shanghai Circode Biomed Co., Ltd. | Circular rna encoding vegf polypeptides, formulations, and methods of uses |
| WO2025067389A1 (en) * | 2023-09-28 | 2025-04-03 | Immorna (hangzhou) Biotechnology Co., Ltd. | Lipid complex nanoparticle for lung-targeted delivery of nucleic acid therapeutic agent |
| WO2025132839A1 (en) | 2023-12-21 | 2025-06-26 | Glaxosmithkline Biologicals Sa | Influenza virus vaccines |
| WO2025140618A1 (zh) * | 2023-12-29 | 2025-07-03 | 康希诺(上海)生物研发有限公司 | 一种用于递送核酸的脂质纳米颗粒及其制备方法和用途 |
| GB202404607D0 (en) | 2024-03-29 | 2024-05-15 | Glaxosmithkline Biologicals Sa | RNA formulation |
| WO2025229572A1 (en) | 2024-05-01 | 2025-11-06 | Glaxosmithkline Biologicals Sa | Epstein-barr virus antigen-encoding messenger ribonucleic acid and antigen protein vaccines |
| WO2026003582A2 (en) | 2024-06-27 | 2026-01-02 | Axelyf ehf. | Lipids and lipid nanoparticles |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| AU679525B2 (en) | 1992-12-04 | 1997-07-03 | Innovir Laboratories, Inc. | Regulatable nucleic acid therapeutic and methods of use thereof |
| EP1195442A3 (en) | 1992-12-04 | 2002-07-31 | Innovir Laboratories, Inc. | Ribozyme amplified diagnostics |
| US5871914A (en) | 1993-06-03 | 1999-02-16 | Intelligene Ltd. | Method for detecting a nucleic acid involving the production of a triggering RNA and transcription amplification |
| JPH09504517A (ja) | 1993-09-27 | 1997-05-06 | スミスクライン・ビーチャム・コーポレイション | カンプトテシン処方物 |
| US5849902A (en) | 1996-09-26 | 1998-12-15 | Oligos Etc. Inc. | Three component chimeric antisense oligonucleotides |
| US5989912A (en) | 1996-11-21 | 1999-11-23 | Oligos Etc. Inc. | Three component chimeric antisense oligonucleotides |
| US5837282A (en) | 1996-10-30 | 1998-11-17 | University Of British Columbia | Ionophore-mediated liposome loading |
| WO1998027104A1 (en) | 1996-12-19 | 1998-06-25 | Yale University | Bioreactive allosteric polynucleotides |
| CA2312006A1 (en) | 1997-12-05 | 1999-06-17 | Lynn Milich | Nucleic acid mediated rna tagging and rna revision |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| IL126731A0 (en) | 1998-10-23 | 1999-08-17 | Intelligene Ltd | A method of detection |
| EP1133513A4 (en) | 1998-11-03 | 2002-07-03 | Univ Yale | MULTI-DOMAIN POLYNUCLEOTIDE MOLECULAR DETECTORS |
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| US7112337B2 (en) * | 1999-04-23 | 2006-09-26 | Alza Corporation | Liposome composition for delivery of nucleic acid |
| AU1086501A (en) | 1999-10-15 | 2001-04-30 | Carnegie Institution Of Washington | Rna interference pathway genes as tools for targeted genetic interference |
| US20040005667A1 (en) | 2000-07-03 | 2004-01-08 | Giuloi Ratti | Immunisation against chlamydia pneumoniae |
| WO2002034771A2 (en) | 2000-10-27 | 2002-05-02 | Chiron Srl | Nucleic acids and proteins from streptococcus groups a & b |
| WO2003018054A1 (en) | 2001-08-31 | 2003-03-06 | Chiron Srl. | Helicobacter pylori vaccination |
| MXPA05013260A (es) | 2003-06-26 | 2006-03-09 | Chiron Corp | Composiciones inmunogenicas para chlamydia trachomatis. |
| ES2505695T3 (es) | 2003-07-31 | 2014-10-10 | Novartis Vaccines And Diagnostics, Inc. | Composiciones inmunógenas para Streptococcus pyogenes |
| GB0410866D0 (en) | 2004-05-14 | 2004-06-16 | Chiron Srl | Haemophilius influenzae |
| CA2566559C (en) | 2004-05-17 | 2014-05-06 | Inex Pharmaceuticals Corporation | Liposomal formulations comprising dihydrosphingomyelin and methods of use thereof |
| US20060051405A1 (en) | 2004-07-19 | 2006-03-09 | Protiva Biotherapeutics, Inc. | Compositions for the delivery of therapeutic agents and uses thereof |
| US7404969B2 (en) | 2005-02-14 | 2008-07-29 | Sirna Therapeutics, Inc. | Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules |
| CN102675432A (zh) | 2005-02-18 | 2012-09-19 | 诺华疫苗和诊断公司 | 来自尿路病原性大肠杆菌的免疫原 |
| EP1858920B1 (en) | 2005-02-18 | 2016-02-03 | GlaxoSmithKline Biologicals SA | Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli |
| AU2006235045A1 (en) | 2005-03-30 | 2006-10-19 | J. Craig Venter Institute, Inc. | Haemophilus influenzae type b |
| EP1891096A2 (en) | 2005-05-12 | 2008-02-27 | Novartis Vaccines and Diagnostics, Inc. | Immunogenic compositions for chlamydia trachomatis |
| AU2006293180A1 (en) | 2005-09-20 | 2007-03-29 | Jitsubo Co., Ltd. | Carrier for separation, method for separation of compound, and method for synthesis of peptide using the carrier |
| AU2006307602A1 (en) | 2005-10-25 | 2007-05-03 | Novartis Vaccines And Diagnostics Srl | Compositions comprising Yersinia pestis antigens |
| EP2064230A2 (en) | 2006-08-16 | 2009-06-03 | Novartis AG | Immunogens from uropathogenic escherichia coli |
| GB0714963D0 (en) | 2007-08-01 | 2007-09-12 | Novartis Ag | Compositions comprising antigens |
| GB0717187D0 (en) | 2007-09-04 | 2007-10-17 | Novartis Ag | Compositions comprising yersinia pestis antigens |
| KR101198354B1 (ko) * | 2007-10-17 | 2013-03-14 | 주식회사 삼양바이오팜 | 핵산 전달용 저밀도 지단백질 유사(ＬＤＬ-ｌｉｋｅ) 양이온성 나노입자, 그의 제조방법 및 이를 이용한 핵산의 전달 방법 |
| ITMI20081249A1 (it) | 2008-07-09 | 2010-01-09 | Novartis Vaccines & Diagnostic | Immunogeni di escherichia coli con solubilità migliorata. |
| US20110110857A1 (en) | 2008-03-06 | 2011-05-12 | Roberto Petracca | Mutant forms of chlamydia htra |
| EP2419129A2 (en) | 2009-04-14 | 2012-02-22 | Novartis AG | Compositions for immunising against staphylococcus aerus |
| WO2011005799A2 (en) | 2009-07-06 | 2011-01-13 | Novartis Ag | Self replicating rna molecules and uses thereof |
| KR101762466B1 (ko) | 2009-12-23 | 2017-07-27 | 노파르티스 아게 | 지질, 지질 조성물 및 이의 사용 방법 |
| US9770463B2 (en) | 2010-07-06 | 2017-09-26 | Glaxosmithkline Biologicals Sa | Delivery of RNA to different cell types |
| US9376467B2 (en) | 2011-03-09 | 2016-06-28 | Jitsubo Co., Ltd. | Cross-linked peptides containing non-peptide cross-linked structure, method for synthesizing cross-linked peptides, and novel organic compound used in method |
| JP2014101274A (ja) * | 2011-03-09 | 2014-06-05 | Jitsubo Co Ltd | 新規な架橋構造を含むｔｎｆレセプターループペプチドの模倣ペプチドを用いた医薬組成物 |
| EP2788006B1 (en) * | 2011-12-07 | 2026-01-07 | Alnylam Pharmaceuticals, Inc. | Biodegradable lipids for the delivery of active agents |
| WO2013089241A1 (ja) * | 2011-12-15 | 2013-06-20 | 味の素株式会社 | Ｆｍｏｃ基の除去方法 |
| US9504747B2 (en) * | 2013-03-08 | 2016-11-29 | Novartis Ag | Lipids and lipid compositions for the delivery of active agents |
| WO2016037053A1 (en) * | 2014-09-05 | 2016-03-10 | Novartis Ag | Lipids and lipid compositions for the delivery of active agents |
| MX2019014435A (es) * | 2017-05-30 | 2020-01-27 | Glaxosmithkline Biologicals Sa | Procedimientos para la fabricacion de un arn encapsulado en liposoma. |
| EP3893927A1 (en) * | 2018-12-14 | 2021-10-20 | GlaxoSmithKline Biologicals S.A. | Heterologous prime boost vaccine compositions and methods |
-
2015
- 2015-09-04 WO PCT/US2015/048535 patent/WO2016037053A1/en not_active Ceased
- 2015-09-04 CN CN201580060043.1A patent/CN107072946B/zh active Active
- 2015-09-04 ES ES15775528T patent/ES2969956T3/es active Active
- 2015-09-04 JP JP2017512684A patent/JP6731912B2/ja active Active
- 2015-09-04 EP EP15775528.1A patent/EP3188760B1/en active Active
- 2015-09-04 US US15/505,282 patent/US10125092B2/en active Active
-
2018
- 2018-09-19 US US16/135,116 patent/US10844002B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017532302A5 (enExample) | ||
| JP2017048194A5 (enExample) | ||
| JP2019194236A5 (enExample) | ||
| JP2016104790A5 (enExample) | ||
| JP2013539454A5 (enExample) | ||
| JP2018520997A5 (enExample) | ||
| JP2018024670A5 (enExample) | ||
| JP2010227108A5 (enExample) | ||
| EA202191418A1 (ru) | Рекомбинантные вирусные векторы и нуклеиновые кислоты для их получения | |
| JP2017186358A5 (enExample) | ||
| JP2020022459A5 (enExample) | ||
| EA201892250A1 (ru) | Вакцина против rsv | |
| JP2011155981A5 (enExample) | ||
| JP2014000092A5 (enExample) | ||
| JP2010065037A5 (enExample) | ||
| JP2015096070A5 (enExample) | ||
| JP2016518328A5 (enExample) | ||
| JP2016153424A5 (enExample) | ||
| JP2017534262A5 (enExample) | ||
| JP2012136541A5 (enExample) | ||
| JP2021502388A5 (enExample) | ||
| JP2018033454A5 (enExample) | ||
| EA201692361A1 (ru) | Лентивирусные векторы | |
| JP2016539629A5 (enExample) | ||
| JP2014129395A5 (enExample) |